Key result
Early DOAC initiation shows no difference in stroke recurrence or bleeding versus later initiation in AF.
Why the study?
The optimal timing for initiating oral anticoagulation in patients with atrial fibrillation after acute ischemic stroke remains uncertain.
Does early initiation of DOACs reduce the composite of ischemic stroke, sICH, or unclassified stroke in patients with atrial fibrillation and acute ischemic stroke?
Does early initiation of DOACs reduce the composite of ischemic stroke, sICH, or unclassified stroke in patients with atrial fibrillation and acute ischemic stroke?
Early initiation of DOACs (≤4 days) after acute ischemic stroke in patients with atrial fibrillation appears comparable in safety and efficacy to later initiation (>5 days).
Supports early DOAC initiation as comparably safe; extends pooled evidence confirming no timing difference in post-stroke AF.
Background: The optimal timing for initiating oral anticoagulation in patients with atrial fibrillation after acute ischemic stroke remains uncertain. This systematic review and meta-analysis aims to compare early versus later initiation of oral anticoagulants in this patient population. Methods: We systematically searched multiple databases, including MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov, up to February 2025. We included randomized controlled trials (RCTs) comparing early (≤4 days, post-stroke) versus later (>5 days) direct oral anticoagulation (DOAC) initiation in patients with atrial fibrillation and acute ischemic stroke. Our main outcomes were a primary composite outcome of ischemic stroke, sICH, or unclassified stroke, and the primary composite outcome, or all-cause mortality. Results: Four RCTs were included with a total of 6,722 patients. Our meta-analysis revealed no significant difference between early and later DOAC initiation for the primary composite outcome (RR: 0.84, 95% CI: 0.64–1.09), primary composite outcome or mortality (RR 0.99; 95% CI: 0.82- 1.19), ischemic stroke (RR: 0.78, 95% CI: 0.54–1.12), symptomatic intracranial hemorrhage (RR: 0.96, 95% CI: 0.47–1.96), all-cause mortality (RR: 0.96, 95% CI: 0.81–1.15), or major bleeding (RR: 0.73, 95% CI: 0.28–1.91). Conclusion: Early initiation of anticoagulants appears to be comparable to later initiation in terms of stroke recurrence, bleeding risks, and mortality in patients with atrial fibrillation. These findings support a more individualized approach to anticoagulation timing, balancing ischemic and hemorrhagic risks based on patient characteristics. Further high-quality trials are needed to refine clinical guidelines and optimize anticoagulation strategies in this population.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question. Early initiation of DOACs is not associated with a significant difference in stroke recurrence, bleeding risks, or mortality compared to later initiation in atrial fibrillation patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: